Prentiss Smith & Co. Inc. increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.1% during the third quarter, Holdings Channel reports. The institutional investor owned 73,366 shares of the company’s stock after buying an additional 63 shares during the period. Johnson & Johnson makes up 4.8% of Prentiss Smith & Co. Inc.’s investment portfolio, making the stock its 4th largest position. Prentiss Smith & Co. Inc.’s holdings in Johnson & Johnson were worth $8,667,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in JNJ. Bank of Montreal Can bought a new stake in Johnson & Johnson during the second quarter worth about $858,505,000. Emerald Acquisition Ltd. bought a new stake in Johnson & Johnson during the second quarter worth about $805,455,000. Vanguard Group Inc. boosted its stake in Johnson & Johnson by 2.2% in the second quarter. Vanguard Group Inc. now owns 184,512,652 shares of the company’s stock worth $22,381,384,000 after buying an additional 3,924,090 shares in the last quarter. BlackRock Fund Advisors boosted its stake in Johnson & Johnson by 5.5% in the second quarter. BlackRock Fund Advisors now owns 42,089,045 shares of the company’s stock worth $5,105,401,000 after buying an additional 2,192,319 shares in the last quarter. Finally, Capital World Investors boosted its stake in Johnson & Johnson by 10.3% in the second quarter. Capital World Investors now owns 22,025,323 shares of the company’s stock worth $2,671,672,000 after buying an additional 2,050,323 shares in the last quarter. 64.13% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.53% during trading on Tuesday, reaching $112.53. The company had a trading volume of 4,251,302 shares. The firm has a 50-day moving average price of $115.97 and a 200-day moving average price of $118.40. Johnson & Johnson has a 52-week low of $94.28 and a 52-week high of $126.07. The company has a market capitalization of $306.14 billion, a P/E ratio of 19.75 and a beta of 0.75.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 18th. The company reported $1.68 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.66 by $0.02. Johnson & Johnson had a return on equity of 25.30% and a net margin of 22.03%. The firm had revenue of $17.80 billion for the quarter, compared to the consensus estimate of $17.71 billion. During the same period in the prior year, the business posted $1.49 earnings per share. The firm’s revenue for the quarter was up 4.2% compared to the same quarter last year. On average, analysts predict that Johnson & Johnson will post $6.72 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be given a dividend of $0.80 per share. The ex-dividend date is Friday, November 18th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.29. This represents a $3.20 annualized dividend and a yield of 2.83%. Johnson & Johnson’s dividend payout ratio is 56.64%.

TRADEMARK VIOLATION NOTICE: This article was originally posted by Financial Market News and is the propert of of Financial Market News. If you are reading this article on another website, it was copied illegally and republished in violation of United States & international trademark and copyright legislation. The correct version of this article can be accessed at http://www.financial-market-news.com/johnson-johnson-jnj-is-prentiss-smith-co-inc-s-4th-largest-position/1208785/.

Several equities research analysts have issued reports on the stock. Argus reaffirmed a “buy” rating and set a $145.00 target price on shares of Johnson & Johnson in a research note on Friday, October 21st. Vetr cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $119.60 target price on the stock. in a research note on Tuesday, November 1st. Leerink Swann reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Sunday, September 11th. Barclays PLC cut shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and lifted their target price for the stock from $113.13 to $125.00 in a research note on Tuesday. They noted that the move was a valuation call. Finally, Jefferies Group lifted their target price on shares of Johnson & Johnson from $113.00 to $119.00 and gave the stock a “hold” rating in a research note on Thursday, August 4th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating and eight have issued a buy rating to the company. Johnson & Johnson currently has an average rating of “Hold” and a consensus target price of $121.02.

In other news, Director Charles Prince acquired 875 shares of the business’s stock in a transaction dated Friday, October 21st. The shares were bought at an average cost of $114.11 per share, for a total transaction of $99,846.25. Following the acquisition, the director now directly owns 26,520 shares in the company, valued at approximately $3,026,197.20. The purchase was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.11% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.